biostudies-literatureUnknown17(1)Gavila JInstituto de Salud Carlos IIIF. Hoffmann-La RocheSave the mamaPas a PasTeva Pharmaceutical IndustriesBMC medicine8https://www.ebi.ac.uk/biostudies/studies/S-EPMC6325829biostudies-literatureSafety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial.PMC6325829Not applicablePI16/00904Calvo IPrat AVirizuela JAGonzalez XGavila JLlombart-Cussac ACanes JAndres RQuero JCCiruelos EPerez-Garcia JRuiz IMartinez JOliveira MPerello AMunoz MMorales SMarin-Aguilera MPascual TMartinez DPare LfalseSafety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial.2019-01-01T00:00:00Z2019 Jan2025-04-04T18:56:16.818Z2025-04-04T18:56:16.818ZS-EPMC63258293062169810.1186/s12916-018-1233-1